

AD\_\_\_\_\_

Award Number: DAMD17-00-1-0287

TITLE: Hormone Receptors in Breast Cancer Prognosis - Racial and Quantitative Effects

PRINCIPAL INVESTIGATOR: Carl M. Tammemagi, D.V.M., Ph.D.

CONTRACTING ORGANIZATION: Henry Ford Health System  
Detroit, Michigan 48202

REPORT DATE: June 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> June 2001	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Jun 00 - 31 May 01)	
<b>4. TITLE AND SUBTITLE</b>  Hormone Receptors in Breast Cancer Prognosis - Racial and Quantitative Effects			<b>5. FUNDING NUMBERS</b> DAMD17-00-1-0287	
<b>6. AUTHOR(S)</b>  Carl M. Tammemagi, D.V.M., Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Henry Ford Health System Detroit, Michigan 48202 Email <a href="http://henryford.com">http://henryford.com</a>			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>20011127 034</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. Abstract (Maximum 200 Words)</b> <i>(abstract should contain no proprietary or confidential information)</i> Breast cancer survivors compose the largest group of cancer survivors in the United States. As heterogeneity exists within stages and between races in breast cancer survival, it is important to develop a better understanding of prognostic factors. Tumor estrogen and progesterone receptors are one of the more important prognostic factors in breast cancer patients. However, currently in clinical practice hormone receptor status is treated as either being present or absent and is treated similarly in all groups. The dichotomization of hormone status may lead to loss of valuable information and hormone receptor status may not have the same effect in African Americans and Whites. This historical cohort study evaluates quantitative differences in tumor hormone receptors in African Americans and Whites and determines whether survival effects differ between the two groups. This study also assesses whether a dose-response relationship, linear or nonlinear, exists between hormone receptors and survival. Findings of this study may lead to better prediction of survival and to identification of subsets of patients at higher risk that may have gone unrecognized by the application of a single cutpoint. Our preliminary findings indicate that African American breast cancer patients have more estrogen receptor negativity and a worse survival.				
<b>14. Subject Terms (keywords previously assigned to proposal abstract or terms which apply to this award)</b> Breast cancer survival, African American, estrogen receptor, Progesterone receptor, quantitative analysis			<b>15. NUMBER OF PAGES</b> 27	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	11
Reportable Outcomes.....	11
Conclusions.....	11
References.....	N/A
Appendices.....	12

## INTRODUCTION

Breast cancer survivors compose the largest group of cancer survivors in the United States today. As considerable heterogeneity exists within stages and between racial groups in breast cancer survival it is important to develop a better understanding of prognostic factors. Estrogen and progesterone receptors in breast tumor tissue are regarded to be one of the more important prognostic factors in breast cancer patients. However, currently in clinical practice hormone receptor status is treated as either being present or absent and is treated similarly in all race/ethnic groups. The dichotomization of hormone status may lead to loss of valuable information and hormone receptor status may not have the same effect in African Americans and Whites. This historical cohort study evaluates quantitative differences in estrogen and progesterone receptors in the breast tumors of African Americans and Whites and determines whether survival effects differ between the two groups. This study will also assess whether a dose-response relationship, linear or nonlinear, exists between quantitatively assessed hormone receptors and survival, as opposed to the currently popular dichotomized assessment of receptor status. Findings of this study may lead to better prediction of survival and to identification of subsets of patients needing particular clinical attention that may have gone unrecognized by applying one cutpoint to all patients.

## BODY

Year one of this three-year study has been completed and the items in the *Statement of Work* that should have been undertaken and/or completed are summarized in Table 1.

**Table 1. Progress on items in the *Statement of Works***

	<i>Description</i>	<i>Planned time</i>	<i>Progress</i>
Task 1	Initial establishment of study team, approach and issues	1 to 4 months	Completed
	Staff training	1 to 4 months	Completed
	Preparation of computer programs and study database	1 to 4 months	Completed
Task 2	Establish and Characterize Cohort	4 to 8 months	Completed
	Abstraction of Patient / Tumor Data From	4 to 16 months	
	Computer Databases		Ongoing
	Medical Record Abstraction		Underway
	Hormone Receptor Log Book		Completed
Task 3	SES estimates based on 1990 US Census data	12 to 24 months	Underway
Task 4	Survival Data Collection From		
	Henry Ford Health System Tumor Registry	12 to 24 months	Underway
	SEER	18 to 24 months	Underway
	Michigan State Tumor Registry	18 to 24 months	Underway
Task 5	Attend breast cancer conference	Year two	1 Attended

A study team has been put into place. Ms. Christine Neslund-Dudas, an Epidemiologist I, is helping manage the study, Mr. Richard Krajenta is in charge of the computer databases and data preparation, and Ms. Cheryl Spoutz heads a team of research abstractors who have a minimum of a two-year college degree in Health Information Management (HIM), have passed National Accreditation Examinations and are credentialed Registered Health Information Technicians (RHIT). Currently, Dr. Tammemagi is carrying out all statistical analyses.

All available estrogen and progesterone hormone receptor data (quantitative data) for breast cancer patients from 1982 to 1990 have been manually transcribed from the laboratory notebooks of the Department of Clinical Biochemistry into a Microsoft Access database. Information pertinent to this study was extracted from the Henry Ford Health System (HFHS) Tumor Registry for breast cancer patients during the same period and was placed into another Microsoft Access file.

Survival data has been collected from the HFHS Tumor Registry. Survival and other relevant clinicopathologic data have been collected from the Detroit Surveillance, Epidemiology and End Results (SEER) Tumor Registry. Also, death data for the breast cancer cohort has been downloaded from the Michigan Death Registry files and includes deaths up until the year 1999. These data have been placed in another Access database.

Socioeconomic status (SES) data was estimated for breast cancer patients (1982-1990) in the HFHS Tumor Registry based on patient's address at diagnosis and the block group medium household income (BGMHI) derived from the 1990 US Census. So far we have obtained SES estimates for approximately 70% of individuals, which is below what we have obtained in several past studies. We will be investigating alternative computer algorithms for collecting these data, including attempting to collect SES data for individuals living outside of the Metropolitan Detroit area.

As these databases are completed and cleaned up they will be merged. One issue that we are addressing is conflicting survival follow-up data. The HFHS Tumor Registry is usually current to up to within 6 months, whereas the SEER Tumor Registry is usually about 1 year behind in updating its files. Thus, one would expect the HFHS Tumor Registry to be preferred, however, the SEER Tumor Registry and the Michigan Death Registry data may capture survival

events lost to follow-up in the HFHS, and the latter will provide specific causes of death data. Each conflicting survival case will be assessed individually.

A good deal of effort in the last year has gone into developing and testing the *Data Abstraction Form*. A copy is provided in Appendix 1. It has gone through four cycles of testing and re-writing and re-testing. It has recently undergone a reliability test in which several abstractors abstracted four sets of medical records. The abstraction process demonstrated a high degree of consistency. The average time to complete the abstraction of one patient's medical records was 1.5 hours. Our recent studies in cancer survival have found that comorbidity may play an important role, and that its distribution may differ by race. To ensure adequate adjustment in analysis and attempt to better understand the racial differences in breast cancer survival we have incorporated a section on comorbidity into the abstraction form. Intensive medical record abstraction is about to commence and we hope to complete the majority of it by the end of year two. Dr. Tammemagi will review each abstraction form for completeness and consistency within one week of the abstraction and prior to data entry, so as to allow immediate handling of problems or issues.

Dr. Tammemagi attended the Summit Meeting Evaluating Research on Breast Cancer in African American Women, in Washington, DC, September 8-10, 2000.

To enhance analytic capabilities Dr. Tammemagi purchased S-Plus 2000 (Insightful Corporation, Seattle, WA), and CART (classification and regression tree) and MARS (multivariate adaptive regression spline) (Salford Software Inc., San Diego, CA) software packages. Dr. Tammemagi attended a three-day training course on the use of the latter two programs in Toronto, in October 2000. Dr. Tammemagi also met with Dr. Michael LeBlanc in

Seattle, WA, and had Dr. LeBlanc's tree-based survival software installed on his laptop computer and received instruction on its use.


### **Preliminary Study Findings**

Although the study is still in the early stages, an impression of the study population and data is offered. It must be emphasized that the data presented are preliminary and are likely to change – datasets are not complete and data has not been “cleaned”.

The non-finalized dataset includes 1161 patients of whom 824 (71%) are whites and 337 (29%) are Black. The mean patient age is 60.1 years (SD 14.2) and the minimum, median and maximum ages are 24, 61, 94 years, respectively. The median follow-up of the breast cancer cohort is 11.4 years (95% CI 10.6-12.5). The median survival for African Americans was 10.6 (95% CI 9.1-12.2) years versus 11.6 (95% CI 10.6-13.3) years for Whites. A Kaplan-Meier survival plot describing the survival experience for these two groups is presented in Figure 1.




**Figure 1. Kaplan-Meier survival plot describing the survival experience of 956 breast cancer patients diagnosed in the HFHS (1982-1990)**



The hormone receptor data presented here are for 1041 individuals. The overall geometric mean for estrogen receptors is 26.84, and for African Americans is 19.74 and for Whites is 30.54. These preliminary data together with the density distribution plot for  $\log(\text{estrogen receptor})$  (Figure 2) suggest that African Americans have more receptor negative tumors and possibly more positive tumors with lower counts.

**Figure 2. Density distribution plot of  $\log(\text{estrogen receptor})$  stratified by race**



**KEY RESEARCH ACCOMPLISHMENTS: NA.**

**REPORTABLE OUTCOMES: NA.**

**CONCLUSIONS**

It is too early into the study to draw any substantive or methodologic conclusions. However, the study is progression on schedule and within budget, and expects to present a more exciting report next year.

**APPENDIX 1. JFCC – *Hormone Receptors & Breast Cancer Survival Study Abstraction***  
***Form***

<b>Study ID #:</b> _____	<b>Abstraction Date:</b> ____/____/____
<b>Abstraction Time:</b> _____	<b>Abstractor ID:</b> _____
(use month/day/ year throughout)	

**CASE DESCRIPTION & EPIDEMIOLOGIC DATA**

**CONFIRMATION OF CASE STATUS**

Is there evidence in the chart that the patient was diagnosed with invasive breast cancer or suspicion of invasive breast cancer on the same date (or within 2 weeks of the date) as it appears as the "Diagnosis Date" for the Josephine Ford Cancer Registry?

**If Yes** → Continue.

Record original JFCC dx date here: \_\_\_\_/\_\_\_\_/\_\_\_\_

**If No** → Do alternative breast cancer diagnosis dates exist?  
Please enter the dates here:

1. \_\_\_\_/\_\_\_\_/\_\_\_\_

2. \_\_\_\_/\_\_\_\_/\_\_\_\_

3. \_\_\_\_/\_\_\_\_/\_\_\_\_

If you are unable to confirm diagnosis of invasive breast cancer, **STOP REVIEW** and consult with investigator.

**SOCIODEMOGRAPHIC DATA** (Complete only if it differs from that provided, i.e., JFCC Tumor Registry data)

**Date of Birth:** \_\_\_\_/\_\_\_\_/\_\_\_\_

**Race**

1 = White

2 = Black / African American

3 = American Indian or Alaskan Native

4 = Asian

5 = Pacific Islander or Native Hawaiian

6= Other, specify \_\_\_\_\_

9 = Unknown

**Ethnicity** 0= Non-Hispanic 1 = Hispanic

**Marital Status at diagnosis**

1= Married or living as married

2 = Not married 2a = Single (never married)

2b = Divorced or legally separated

2c = Widowed

9= Unknown

**BODY SIZE INFORMATION (exclude data during pregnancy)**

Maximum Height (inches): _____	Date: ____ / ____ / ____
Weight closest to <b>diagnosis date</b> (pounds): _____	Date: ____ / ____ / ____

**REPRODUCTIVE / ENDOCRINE HISTORY**

<b>Age at menarche (years)</b> _____	
<b>Menopausal status at diagnosis.</b> 01= Pre-menopausal 02= Peri-menopausal (Transition between pre- & post-menopause. Menstrual cycles irregular, hot flashes.) 03= Post-menopausal When did menopause occur? _____ Year/age/years ago? 04= Hysterectomy. Number of ovaries removed? _____ Date of surgery: ____ / ____ / ____ 99=Undetermined	
<b>Parity (# of live births) as of the diagnosis date.</b> ____	
<b>If pre-menopausal, record the number of post-diagnosis live births</b> ____	
<b>Did the patient use hormone contraceptives?</b> 0=No    1=Yes    9=Unknown	
Start date of use: ____ / ____ / ____ Length of time (years): _____ Product Name: _____	Type : 1=Birth Control Pills 2=Shots or Injections 3=Subdermal Implants
Start date of use: ____ / ____ / ____ Length of time (years): _____ Product Name: _____	Type: 1=Birth Control Pills 2=Shots or Injections 3=Subdermal Implants
Start date of use: ____ / ____ / ____ Length of time (years): _____ Product Name: _____	Type: 1=Birth Control Pills 2=Shots or Injections 3=Subdermal Implants
<b>Did the patient use hormone replacement therapy?</b> 0=No    1=Yes    9=Unknown	
Start date of use: ____ / ____ / ____ Length of time (years): _____ Product Name: _____	1=Estrogen Alone 2=Estrogen plus Progesterone 3=Progesterone Alone
Start date of use: ____ / ____ / ____ Length of time (years): _____ Product Name: _____	1=Estrogen Alone 2=Estrogen plus Progesterone 3=Progesterone Alone
Start date of use: ____ / ____ / ____ Length of time (years): _____ Product Name: _____	1=Estrogen Alone 2=Estrogen plus Progesterone 3=Progesterone Alone

**FAMILY HISTORY OF BREAST CANCER****Is there a family history of breast cancer?**

1= Yes, there is a noted family history

2= No, there is a noted negative family history

8 = record shows Ø

9=Undetermined, not documented

**MAMMOGRAPHY HISTORY****Mammography History from 3 years prior to first treatment:**

0=No 1=Yes 9=Unknown

**If yes, complete the following table**

Dates:

Results:

Results Key:

1. \_\_\_\_/\_\_\_\_/\_\_\_\_

2. \_\_\_\_/\_\_\_\_/\_\_\_\_

3. \_\_\_\_/\_\_\_\_/\_\_\_\_

4. \_\_\_\_/\_\_\_\_/\_\_\_\_

5. \_\_\_\_/\_\_\_\_/\_\_\_\_

6. \_\_\_\_/\_\_\_\_/\_\_\_\_

7. \_\_\_\_/\_\_\_\_/\_\_\_\_

8. \_\_\_\_/\_\_\_\_/\_\_\_\_

9. \_\_\_\_/\_\_\_\_/\_\_\_\_

10. \_\_\_\_/\_\_\_\_/\_\_\_\_

11. \_\_\_\_/\_\_\_\_/\_\_\_\_

12. \_\_\_\_/\_\_\_\_/\_\_\_\_

13. \_\_\_\_/\_\_\_\_/\_\_\_\_

14. \_\_\_\_/\_\_\_\_/\_\_\_\_

15. \_\_\_\_/\_\_\_\_/\_\_\_\_

16. \_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

1= Negative

2= Benign/Negative

3= Probably Benign

4= Suspicious

5= Highly Suspicious

8= Incomplete/Inconclusive

9= Unknown

**PATIENT HISTORY OF BREAST LESIONS BEFORE THE INDEX BREAST CANCER****Breast Biopsy History throughout patient records**

0=No 9=Unknown

1=Yes If yes, complete table below

Dates

Results

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

\_\_\_\_/\_\_\_\_/\_\_\_\_

Key to Results:

1. Benign Breast Disease (BBD)

2. Ductal Carcinoma In Situ (DCIS)

3. Lobular Carcinoma In Situ (LCIS)

4. Both BBD and CIS/Cancer

5. Invasive Carcinoma (specify histopathologic type)

6. Lumpectomy or Mastectomy (unilateral or bilateral) not further specified

7. Cosmetic Breast Reduction

8. Cosmetic Breast Enlargement

9. Other Breast Biopsy (epithelial biopsy of breast skin, nipple, fat, axillary lymph nodes, etc.)

99. Incomplete/Inconclusive Unknown

**SYMPTOMS AND LEAD-UP TO THE DIAGNOSIS OF BREAST CANCER**

When was the first time that a suspicion of breast cancer for this index case of breast cancer was documented in medical records or indicated by a medical procedure? \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Did patient report breast symptoms?

- ☐ 01=Yes → If yes, please continue with the next question.  
☐ 02=No. Explicit mention of no symptoms → If no, skip to next box.  
☐ 99=No comment about symptoms → Skip to next box.

Patient Reported Breast Symptoms  
*(Indicate all that apply.)*

**L R Unk**

- ☐ ☐ ☐ 01=Lump or mass  
☐ ☐ ☐ 02=Pain *Specify:* \_\_\_\_\_  
☐ ☐ ☐ 03=Nipple discharge  
☐ ☐ ☐ 04=Visual change  
☐ ☐ ☐ 05=Odor  
☐ ☐ ☐ 88=Other, *specify:* \_\_\_\_\_  
☐ ☐ ☐ 99=Unspecified

**Date Documented**

**Duration**

_____	_____
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

**PATHOLOGY SUMMARIES of the specimens related to the index breast cancer.**

**If cytology, biopsy and surgical excision were involved, please complete for each procedure.**

**CYTOLOGY**

*(Indicate all that apply for each breast.)*

Date of procedure: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**L R Unk**

**Results**

- ☐ ☐ ☐ 00=Insufficient sample  
☐ ☐ ☐ 01=Normal cells  
☐ ☐ ☐ 02=Atypical cells  
☐ ☐ ☐ 03=Abnormal cells  
☐ ☐ ☐ 04=Malignant cells,  
specify type \_\_\_\_\_  
☐ ☐ ☐ 88=Other, *specify:* \_\_\_\_\_  
☐ ☐ ☐ 99=Undetermined

Photocopy report masking patient identifiers

*(Indicate all that apply for each breast.)*

Date of procedure: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

- ☐ ☐ ☐ 00=Insufficient sample  
☐ ☐ ☐ 01=Normal cells  
☐ ☐ ☐ 02=Atypical cells  
☐ ☐ ☐ 03=Abnormal cells  
☐ ☐ ☐ 04=Malignant cells,  
specify type \_\_\_\_\_  
☐ ☐ ☐ 88=Other, *specify:* \_\_\_\_\_  
☐ ☐ ☐ 99=Undetermined

Photocopy report masking patient identifiers

*(Indicate all that apply for each breast.)*

Date of procedure: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

- ☐ ☐ ☐ 00=Insufficient sample  
☐ ☐ ☐ 01=Normal cells  
☐ ☐ ☐ 02=Atypical cells  
☐ ☐ ☐ 03=Abnormal cells  
☐ ☐ ☐ 04=Malignant cells,  
specify type \_\_\_\_\_  
☐ ☐ ☐ 88=Other, *specify:* \_\_\_\_\_  
☐ ☐ ☐ 99=Undetermined

Photocopy report masking patient identifiers



**Continued, PATHOLOGY SUMMARY of the specimens related to the index breast cancer.**  
**If cytology, biopsy & surgical excision were involved complete for each procedure.**

<b>HISTOPATHOLOGY FROM BIOPSY</b>		<b>L</b>	<b>R</b>	<b>Unk</b>	<b>Results</b>
(Indicate <u>all</u> that apply for <u>each</u> breast.)		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	01= Atypical hyperplasia
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	02= Ductal hyperplasia
Date of procedure: ____ / ____ / ____		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	03= Fibroadenoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	04= Intraductal carcinoma in situ (DCIS)
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	05= Lobular carcinoma in situ (CIS)
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	06= CIS not otherwise specified
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<b>07= Invasive ductal carcinoma (DC)</b>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	08= Invasive DC with DCIS
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	09= Invasive lobular carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10= Mucinous carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11= Medullary carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	12= Papillary carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13= Tubular carcinoma
Photocopy report masking patient identifiers		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14= Adenoid cystic carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	15= Secretory (juvenile) carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	16= Apocrine carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	17= Paget's disease of the nipple
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	18= Invasive cancer, NOS
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	19= Cystosarcoma phyllodes
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	88= Other, <i>specify</i> : _____
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	99= Undetermined

<b>HISTOPATHOLOGY -- SURGICAL EXCISION</b>		<b>L</b>	<b>R</b>	<b>Unk</b>	<b>Results</b>
(Indicate <u>all</u> that apply for <u>each</u> breast.)		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	01= Atypical hyperplasia
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	02= Ductal hyperplasia
Date of procedure: ____ / ____ / ____		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	03= Fibroadenoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	04= Intraductal carcinoma in situ (DCIS)
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	05= Lobular carcinoma in situ (CIS)
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	06= CIS not otherwise specified
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<b>07= Invasive ductal carcinoma (DC)</b>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	08= Invasive DC with DCIS
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	09= Invasive lobular carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10= Mucinous carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11= Medullary carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	12= Papillary carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13= Tubular carcinoma
Photocopy report masking patient identifiers		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14= Adenoid cystic carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	15= Secretory (juvenile) carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	16= Apocrine carcinoma
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	17= Paget's disease of the nipple
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	18= Invasive cancer, NOS
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	19= Cystosarcoma phyllodes
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	88= Other, <i>specify</i> : _____
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	99= Undetermined

**STAGING**

PLEASE PHOTOCOPY PATHOLOGISTS REPORTS minus patient identifiers	
Primary Tumor (T)	<input type="checkbox"/> TX Primary tumor cannot be assessed <input type="checkbox"/> TO No evidence of primary tumor <input type="checkbox"/> Tis Carcinoma in situ <input type="checkbox"/> T1 Tumor ≤2 cm in greatest dimension <input type="checkbox"/> pT1mic Microinvasion 0.1 cm or less in greatest dimension <input type="checkbox"/> T1a Tumor >0.1 to ≤0.5 cm in greatest dimension <input type="checkbox"/> T1b >0.5 to ≤1 cm in greatest dimension <input type="checkbox"/> T1c >1cm to ≤2 cm in greatest dimension <input type="checkbox"/> T2 Tumor >2 cm to 5 cm <input type="checkbox"/> T3 Tumor >5 cm <input type="checkbox"/> T4 Tumor of any size with direct extension to chest wall or skin <input type="checkbox"/> T4a Extension to chest wall <input type="checkbox"/> T4b Edema or ulceration of the skin or satellite skin nodules confined to same breast <input type="checkbox"/> T4c Both T4a and T4b <input type="checkbox"/> T4d Inflammatory carcinoma <p>Paget's disease associated with a tumor is classified by size of the tumor</p>
Regional Lymph Nodes (N)	<input type="checkbox"/> NX Regional LN cannot be assessed (e.g., previously removed or were not sampled) <input type="checkbox"/> N0 No regional LN metastasis <input type="checkbox"/> N1 Spread to movable ipsilateral axillary LN(s) <input type="checkbox"/> N2 Spread to ipsilateral axillary LN(s) fixed to one another or to other structures <input type="checkbox"/> N3 Spread to ipsilateral internal mammary LN(s)
Pathologic Classification (pN)	<input type="checkbox"/> pNX Regional LNs cannot be assessed <input type="checkbox"/> pNO No regional LN metastasis <input type="checkbox"/> pN1 Metastasis to movable ipsilateral axillary LN(s) <input type="checkbox"/> pN1a Only micrometastasis (none larger than 0.2 cm) <input type="checkbox"/> pN1bi Metastasis in 1 to 3 LMs, >0.2 to <2cm in greatest dimension <input type="checkbox"/> pN1bii Metastasis to 4 or more LNs, >0.2 to <2cm in greatest dimension <input type="checkbox"/> pN1biii Extension of tumor beyond capsule of a LN <2 cm in greatest dimension <input type="checkbox"/> pN1biv Metastasis to LN ≥2 cm in dimension <input type="checkbox"/> pN2 Metastasis to ipsilateral axillary LNs that are fixed to other LN(s) or structures <input type="checkbox"/> pN3 Metastasis to ipsilateral internal mammary LN(s)
Distant Metastasis	<input type="checkbox"/> MX <input type="checkbox"/> M0 <input type="checkbox"/> M1 (includes metastasis to ipsilateral supraclavicular LN(s)) <p>If M=1, what are the number of metastatic organ sites? _____</p> <p>Specify sites (which organs) _____</p>
What was the TNM stage group, if provided?	<input type="checkbox"/> 0 (TIS) <input type="checkbox"/> I <input type="checkbox"/> II <input type="checkbox"/> IIA <input type="checkbox"/> IIB <input type="checkbox"/> III <input type="checkbox"/> IIIA <input type="checkbox"/> IIIB <input type="checkbox"/> IV <input type="checkbox"/> Stage X (cannot be determined) <input type="checkbox"/> Not provided
Histopathologic GRADE: _____	<input type="checkbox"/> GX= cannot be assessed <input type="checkbox"/> G1= well differentiated <input type="checkbox"/> G2= moderately differentiated, <input type="checkbox"/> G3= poorly differentiated <input type="checkbox"/> G4= Undifferentiated <input type="checkbox"/> G9 = Unknown

**TREATMENT**

<b>Did the patient received treatment?</b>	1 = treatment carried out (mostly at HFHS) 2 = treatment primarily carried out elsewhere 3 = treatment interrupted / incomplete 4 = treatment advised but refused 5 = no treatment advised 6 = no treatment given, reasons unknown 9 = unknown whether treatment received
<b>Was the breast cancer treated with SURGERY?</b> 0 = no 1 = yes 9 = unknown	If yes, what was the date? (1 <sup>st</sup> if more than one) ____/____/_____ Surgery consisted of 1 = breast conserving surgery (lumpectomy, wide excision, partial mastectomy, segmental mastectomy or quadrantectomy) 2 = total mastectomy without axillary lymph node dissection 3 = modified radical mastectomy (simple mastectomy + lymph node dissection) 4 = radical mastectomy (includes pectoral muscle dissection)
<b>Was the breast cancer treated with RADIATION?</b>	<b>0 = no 1 = yes 9 = unknown</b> If yes, what was the start date? ____/____/_____ 
<b>Was the breast cancer treated with CHEMOTHERAPY?</b> 0 = no 1 = yes 9 = unknown	If yes, what was the start date? ____/____/_____ What were the agents? _____ _____ _____ _____ _____ _____
<b>Was the breast cancer treated with HORMONE OR ENDOCRINE THERAPY?</b> 0 = no 1 = yes 9 = unknown	If yes, what was the start date? ____/____/_____ What were the agents? _____ _____ _____ _____ _____
Was tamoxifen given? 0 = no 1 = yes 9 = unknown      When was it started? ____/____/_____ <div style="text-align: right;">For what duration was it administered? _____</div>	

**RESPONSE and FOLLOW-UP**

Did cancer recur or spread (local or distant progression)? 0=no 1=yes 9=unknown	
If yes, When was it 1 <sup>st</sup> noted? ____/____/____ To where? _____	
What was the diagnosis of recurrence/progression based on 1=pathology 2=clinical 3=both 9=not stated?	
Did the patient develop one or more subsequent primary (new) breast cancers?	
0=no 1=yes Histopathologic dx? _____	Date? ____/____/____
0=no 1=yes Histopathologic dx? _____	Date? ____/____/____
0=no 1=yes Histopathologic dx? _____	Date? ____/____/____
Did the patient develop other types of primary cancer?	
0=no 1=yes Type of cancer? _____	Date? ____/____/____
0=no 1=yes Type of cancer? _____	Date? ____/____/____
0=no 1=yes Type of cancer? _____	Date? ____/____/____
Do the records indicate that the patients died? 0=no 1=yes If yes, what was the death date? ____/____/____	
If patient died, were causes of death described? 0 = no 1 = yes	If yes, what were the causes of death? _____ _____ _____
If the patient was alive at last contact, what was the date of the last contact? ____/____/____	

**ALCOHOL USE (documented 5 years before to 3 years after diagnosis)**

Regarding ALCOHOL consumption the records indicate the following:				
0 = Abstained from alcohol / No consumption 1 = Mild use (past or present) 2 = Moderate use (past or present) 3 = Past heavy use 4 = Current heavy use 5 = Heavy use, not otherwise specified 7 = Alcohol was consumed by not quantified 8 = record shows Ø 9 = No alcohol data were available	Date	Date	Date	Date
	Code #	Code #	Code #	Code #

**MARIJUANA/CANNIBIS USE (documented 5 years before to 3 years after diagnosis)**

Regarding MARIJUANA/CANNIBIS use the records indicate the following:				
0 = Non-user 1 = Past regular use 2 = Current regular use 3 = Both past and current use 8 = record shows Ø 9 = No data were available	Date	Date	Date	Date
	Code #	Code #	Code #	Code #

**ILLCIT DRUG USE (documented 5 years before to 3 years after diagnosis)**

**(e.g., cocaine, crack, heroin, or non-specified intravenous drugs, etc. )**

Regarding ILLICIT DRUG use the records indicate the following:				
0 = Non-user 1 = Past regular use 2 = Current regular use 3 = Both past and current use 8 = record shows Ø 9 = No data were available	Date	Date	Date	Date
	Type of drug	Type of drug	Type of drug	Type of drug
	Code #	Code #	Code #	Code #

**SMOKING HISTORY**

Cigarette smoking data was available in the records (documented 5 years before to 3 years after diagnosis) 0=no 1=yes ?

If yes, complete for each recording of smoking history that occurs on a different day or in a different record, even if the data appear redundant.

DATE	Ø smoking	SMOKER 0=Never 1=Ever	SMOKER 0=Never Smoker 2=Past Smoker 3=Current Smoker	QUIT HOW LONG AGO? (in years, use decimals if needed)	INTENSITY cigarettes/ day	C. INTENSITY packs/day	D. DURATION # of years smoked	C x D = PACK-YEARS SMOKED
___/___/___								
___/___/___								
___/___/___								
___/___/___								
___/___/___								
___/___/___								
___/___/___								
___/___/___								

• **COMORBIDITIES**

Please record all of the comorbidities that the records indicate that the patient has had that are reported in the patients records from 3 years prior to diagnosis to 6 months following diagnosis or up until the first treatment, which ever comes first. The comorbidity did not have to have started during this period, it just needed to be documented in the medical records during this time period. As a default all conditions are coded 0, indicating not present. Column A provides a location to mark broader categories of comorbidity and Column B provides a site to mark more specific categories of comorbidities. Please provide as detailed information as possible, identifying (circling) comorbidities in both Columns A and B where possible.

The following systems are listed in the table below in alphabetical order:

**CARDIOVASCULAR**

**ENDOCRINE, METABOLIC & NUTRITIONAL**

Endocrine

Water, Electrolyte, Mineral & Acid-Base Metabolism

Nutritional Disorders

**GASTROINTESTINAL (descending anatomic order)**

**GENITOURINARY TRACT**

**HEMATOLOGIC / ONCOLOGIC**

**IMMUNOLOGIC**

**INFECTIONS**

**MUSCULOSKELETAL / CONNECTIVE TISSUE**

**NEUROPSYCHIATRIC & SENSORY**

**RESPIRATORY**

- • Using the table below to document the patients comorbidities.

<b>CARDIOVASCULAR</b>	
Aneurysm	
Arrhythmia	
Cardiac Arrest	
Cerebrovascular Disease (Stroke)	Cerebrovascular accident (CVA) Transient ischemic attack Plegia associated with CVA
Congestive Heart Failure	
Heart Disease /Coronary Artery Disease	Myocardial Infarct Angina Coronary Artery Bypass Graft (CABG) Angioplasty (PCTA)
Hypertension	Provide representative systolic/diastolic readings _____ Essential (primary) hypertension Secondary (renal) hypertension
Peripheral Vascular Disease	Deep vein thrombosis / Thrombophlebitis Giant cell arteritis
Pulmonary Embolism	
Valve Disease	
Other Heart	Specify: _____
<b>ENDOCRINE, METABOLIC &amp; NUTRITIONAL</b>	
<b>Endocrine</b>	
Diabetes mellitus mild	
Diabetes mellitus Insulin-dependent	
Diabetes mellitus with end organ damage	(Nonketotic Hyperglycemic-Hyperosmolar Coma)
Diabetic Ketoacidosis	
Alcoholic Ketoacidosis	
Hyperglycemia	
Hypoglycemia	
Pituitary Disorders	<b>Anterior Lobe:</b> Hypopituitarism, Hypersecretion (Giantism & Acromegaly, Galactorrhea); <b>Posterior Lobe:</b> Diabetes insipidus (place in renal disease)
Thyroid Disorders	Hyperthyroidism Hypothyroidism Thyroiditis
Adrenal Disease	Hypofunction: Addison's disease; Hyperfunction: Adrenal virilism, Cushing's syndrome; Hyperaldosteronism Pheochromocytoma (chromaffin cells)
Parathyroid Gland	Hypoparathyroidism (see Hypocalcemia) Hyperparathyroidism (see Hypercalcemia)
Multiple Endocrine Neoplasia (MEN) Syndromes	
Polyglandular Deficiency Syndromes	
Amyloidosis	
Lipid problems	Hypercholesterolemia Hyperglyceridemia Other Hyperlipemia / Hyperlipoproteinemia
Other endocrine _____	
<b>Water, Electrolyte, Mineral &amp; Acid-Base Metabolism</b>	
Disorders of Water & Na	Extracellular Fluid Volume Contraction Dehydration Extracellular Fluid Volume Expansion Hyponatremia Hypernatremia= plasma [Na]>145mEq/L)

**JFCC -- Hormone Receptors & Breast Cancer Survival Abstraction Form**

Disorders of Potassium Metabolism:	Hypokalemia = serum [K] <3.5 mEq/L, hyperkalemia = serum [K] >5.5 mEq/L or plasma > 5.0.
Disorders of Calcium Metabolism	Hypocalcemia = total plasma [Ca] <8.8mg/dL (2.20 mmol/L) in presence of normal plasma [protein]. Hypoparathyroidism. Hypercalcemia = total plasma [Ca] > 10.4 mg/dL (2.60 mmol/L)
Disorders of Phosphate Metabolism	Hypophosphatemia = plasma [P] <2.5 mg/dL (0.81 mmol/L) Hyperphosphatemia = plasma [P] > 4.5mg/dL (1.46 mmol/L)
Disorders of Magnesium Metabolism	Hypomagnesemia = plasma [Mg] <1.4 mEq/L (0.70 mmol/L) Hypermagnesemia = plasma [Mg] >2.1 mEq/L (1.05 mmol/L)
Disorders of Acid-Base Metabolism	Metabolic Acidosis / Metabolic Alkalosis Respiratory Acidosis / Respiratory Alkalosis
<b>Nutritional Disorders</b>	
Malnutrition	Starvation Protein-Energy (calorie) Malnutrition Carnitine Deficiency Essential Fatty Acid Deficiency
Vitamin Deficiency, Dependency / Toxicity	<b>Deficiencies:</b> A, D, E, K, Thiamine (B1), Riboflavin (B2), Niacin, B6, Biotin, Pantothenic acid, C. <b>Toxicities:</b> A, D, E, K, B6,
Mineral Deficiency / Toxicity	Iron, Iodine, Fluorine, Zinc, Chromium, Selenium, Manganese, Molybdenum, Copper,
Obesity	"Eye-ball test" BMI men>27.8, women>27.3
Anorexia	
Other Endocrine, Metabolic, Nutritional	Specify: _____
<b>GASTROINTESTINAL (descending anatomic order)</b>	
Esophageal disease	
Gastroesophageal reflux disease (GERD)	
Gastritis and Ulcer	Gastritis Peptic Ulcer Disease
Liver Disease	Fatty Liver Alcoholic Liver Disease Fibrosis Cirrhosis Hepatitis (acute vs. chronic) Drug-induced Liver Damage Hepatic Granulomas Vascular Lesions
Extra-hepatic Biliary Disorders (Gall Bladder Disease)	Cholelithiasis, Cholecystitis, Choledocholithiasis, Primary Sclerosing Cholangitis, Cholesterolosis of Gallbladder, Diverticulosis of gallbladder.
Pancreatic disease	Acute Pancreatitis Chronic Pancreatitis
Diverticulitis / Diverticulosis / Hiatal hernia	
Gastroenteritis	Infectious Chemical Drug-related
Gastrointestinal Bleeding	
Gastrointestinal Polyps	
Malabsorption Syndromes	
Inflammatory Bowel Diseases	Crohn's Disease Ulcerative Colitis
Functional Bowel Diseases	Irritable Bowel Syndrome
Anorectal Disorders	
Other GIT	Specify: _____
<b>GENITOURINARY TRACT</b>	
Renal Disease	Acute Renal failure



**JFCC -- Hormone Receptors & Breast Cancer Survival Abstraction Form**

	Chronic Renal Failure Dialysis Nephritis / Nephropathy / Nephrosis / Upper urinary tract, acute vs. chronic; pyelonephritis, glomerulonephritis. Diabetes insipidus (nephrogenic or pituitary gland disorder) Other Kidney: Specify _____
Urinary Tract Disease	Urolithiasis (stones): Calcium oxalate; uric acid; cystine; struvite = magnesium ammonium phosphate (MAP).
	Lower urinary tract, acute vs. chronic; cystitis, acute vs. chronic; Incontinence
<b>GYNECOLOGIC &amp; OBSTETRICAL</b>	
Menstrual Abnormalities / Abnormal Uterine Bleeding	Primary (Functional) Dysmenorrhea (painful ovulatory cycle) Secondary (Acquired) Dysmenorrhea Amenorrhea Dysfunctional Uterine Bleeding
Premature Ovarian Failure (Premature Menopause) (<40yr)	
Endometriosis	
Uterine Fibroids (leiomyoma; myoma; fibromyoma)	
Pelvic Inflammatory Disease – Infection of the upper female genital tract	Endometritis (uterus) Salpingitis (fallopian tubes) Mucopurulent cervicitis (cervix) Oophoritis (ovaries)
Vulvovaginal Infections	Specify Agent: _____
Other Gynecologic or Obstetrical	Specify: _____
<b>HEMATOLOGIC / ONCOLOGIC</b>	
Anemia	
Electrolyte Imbalance	
Blood Disorders	
Other Hematologic _____	
Cancer	Non-metastatic >10 years ago Non-metastatic 0-10 years ago Metastatic cancer (any time ago)
Other Hematologic / Oncologic	Specify: _____
<b>IMMUNOLOGIC</b>	
Major Immunologic	Systemic lupus erythematosus (SLE) Systemic sclerosis Polymyositis Sarcoidosis
Allergic Reactions to Drugs, Foods, Hay fever, Other.	Specify: _____
Toxicity or Adverse Reactions	Specify: _____
<b>INFECTIONS</b>	
Encephalitis / Meningitis	
HIV / AIDS	
Gastroenteritis	
Sexually Transmitted Disease (STD)	Syphilis
Septicemia	
Tuberculosis (TB)	Active and under current Rx or old, inactive case.
Other Infections _____	Chicken pox, Herpes simplex, Measles, Mononucleosis (mono), Mumps, Poliomyelitis (polio), Shingles zoster, Toxoplasmosis

<b>MUSCULOSKELETAL / CONNECTIVE TISSUE</b>	Arthritis Osteoarthritis/degenerative Joint disease Other Arthritis Inflammatory arthritis Rheumatoid arthritis Polymyalgia rheumatics
Arthritis – Rheumatoid	
Arthritis – Non-Rheumatoid / Non-Immune	
Osteoporosis / Osteopenia	
Adult Fractures	
Amputation	
Other Connective Tissue _____	Specify: _____
<b>NEUROPSYCHIATRIC &amp; SENSORY</b>	
Ophthalmic/ Eye Problems	Cataracts Glaucoma
Hearing problems/ disorder	
Psychiatric Disorders	Depression Paranoid / residual unspecified Schizophrenia Bipolar affective disorder Manic-depressive/unspecified psychosis Paranoia Anxiety states Phobic disorders Unspecified neurotic disorders
Dementia	
Neurologic	Parkinson's disease Multiple sclerosis Amyotropic lateral sclerosis
Migraine headaches	
Seizure / Epilepsy / Convulsions	
Other Neuropsychiatric or Sensory	Specify: _____
<b>RESPIRATORY</b>	
Chronic Obstructive Pulmonary Disease	
Emphysema	
Chronic Bronchitis	
Asthma	
Pneumonia	Recurrent Pneumonia Post-obstructive pneumonia
Pulmonary Fibrosis	Diffuse interstitial / infiltrative / restrictive disease
Other Respiratory _____	

- **Please list all medications taken by the patient for 3 years prior to the breast cancer diagnosis.**  
 Exclude the oral contraceptives & hormone replacement therapies listed previously.

<b>Medication</b>	<b>Indication if given</b>	<b>Estimate Usage</b> 1 = Short term (< 6 months) 2 = Long term (≥ 6 months) 9 = unknown

**ADDITIONAL INFORMATION / SUMMARY**

If the chart information was incomplete or otherwise insufficient, check box and specify below.

☐ 01=Yes

Comments:

Record any additional comments about this case: